Press Room

Press Release

Maria Maccecchini, President and CEO of QR Pharma, Inc. to Serve on Panel with Nobel Laureate, Phillip Sharp at Chemical Heritage Foundation Event

Berwyn, Pennsylvania, May 11, 2015 – Maria Maccecchini, PhD, President and CEO of QR Pharma, Inc. and Philip A. Sharp will be discussing “Secrets of a Science: Challenges and Opportunities of Biomedical Research”. The conversation will span the progress of Science from its beginnings into the future. The event is part of a Heritage Day

Press Release

Paul Blake, Hal Broderson and Franz Hefti Join QR Pharma Board Company Taps Region’s Proven Experts in Growing Successful Companies

Radnor, PA, June 1, 2009 QR Pharma, Inc., a specialty pharmaceutical company focused on developing novel therapeutics for the treatment of Alzheimer’s disease (AD), today announced the election of Paul Blake, MD, Hal Broderson, MD, MBA and Franz Hefti, PhD to the QR Board of Directors. These appointments follow the recent announcement that QR raised

Press Release

QR Pharma Announces New Scientific Advisory Board with Appointment of World-Class Neurodegenerative Disease Experts

Four Neurology Experts Join Advisory Board Following Recent Breakthrough Discoveries Regarding Posiphen Mechanism of Action Berwyn, PA, January 24, 2017 — QR Pharma, Inc., a privately held Phase 2 biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, today announced the appointment of four world-class key opinion leaders to

Press Release

New Data on Posiphen in Traumatic Brain Injury

QR Pharma, Inc. Presents New Data on Posiphen in Traumatic Brain Injury at 2016 Military Health System Research Symposium–Posiphen Reverses Behavioral Deficits and Neuropathology Caused by Traumatic Brain Injury–Berwyn, Pa., August 17, 2016 — QR Pharma, Inc., a privately held Phase 2 biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other

Scroll to Top